Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
Journal of Pathology and Translational Medicine. 2021;55(6):398-405 
Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients
Journal of the Egyptian National Cancer Institute. 2018;30(4):125-131
Prognostic implications of stromal tumor-infiltrating lymphocytes and programmed death ligand 1 expression in HER2-positive invasive breast cancer
. 2020;
Prognostic significance of programmed cell death ligand 1 (PD-L1), CD8+ tumour-infiltrating lymphocytes, and P53 in non-small cell lung cancer: An immunohistochemical study
Respiratory Medicine. 2017;132:269-270
Prognostic implications of stromal tumor-infiltrating lymphocytes and programmed death ligand 1 expression in HER2-positive invasive breast cancer
. 2020;
JCSE01.14 Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand-1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues
Journal of Thoracic Oncology. 2018;13(10):S313
Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy
International Journal of Hyperthermia. 2018;35(1):591-598
Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer
Cellular & Molecular Immunology. 2010;7(5):389-395
Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
Cancer Cell International. 2021;21(1):
Programmed cell death ligand 1 expression in cytologic and surgical non–small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations
Cancer Cytopathology. 2019;127(7):447-457